DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-12.43%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$367M
AUM Growth
+$367M
(-4.4%)
Cap. Flow
+$50M
Cap. Flow
% of AUM
13.63%
Top 10 Holdings %
Top 10 Hldgs %
47.4%
Holding
97
New
3
Increased
39
Reduced
15
Closed
7
Top Buys
| 1 |
SPDR S&P Biotech ETF
XBI
|
$25.5M |
| 2 |
Ascendis Pharma
ASND
|
$10.1M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$4.74M |
| 4 |
Adicet Bio
ACET
|
$3.21M |
| 5 |
Edgewise Therapeutics
EWTX
|
$2.7M |
Top Sells
| 1 |
Biomea Fusion
BMEA
|
$2.96M |
| 2 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$2.53M |
| 3 |
Athira Pharma
ATHA
|
$2.17M |
| 4 |
Cogent Biosciences
COGT
|
$1.67M |
| 5 |
Immunocore
IMCR
|
$1.61M |
Sector Composition
| 1 | Healthcare | 80.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Apellis Pharmaceuticals
APLS
$3.51B
| $4.38M | 1.19% |
96,935
+3,000
| +3% | +$136K |
|
|
MORF
27
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $4.24M | 1.16% |
195,467
+14,000
| +8% | +$304K |
|
|
CSII
28
DELISTED
Cardiovascular Systems, Inc.
CSII
| $4.12M | 1.12% |
286,988
| – | – |
|
29
Century Therapeutics
IPSC
$40.4M
| $3.99M | 1.09% |
475,367
+218,475
| +85% | +$1.84M |
|
|
ISEE
30
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $3.87M | 1.06% |
402,476
+104,000
| +35% | +$1M |
|
|
TPTX
31
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $3.65M | 0.99% |
48,452
-11,000
| -19% | -$828K |
|
|
FSTX
32
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $3.61M | 0.98% |
576,881
-116,904
| -17% | -$732K |
|
|
OTIC
33
DELISTED
Otonomy, Inc.
OTIC
| $3.06M | 0.83% |
1,470,199
-27,315
| -2% | -$56.8K |
|
34
AtriCure
ATRC
$1.73B
| $2.94M | 0.8% |
72,029
| – | – |
|
|
KNTE
35
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $2.83M | 0.77% |
224,451
+76,300
| +52% | +$962K |
|
36
Axogen
AXGN
$718M
| $2.72M | 0.74% |
332,103
| – | – |
|
37
KalVista Pharmaceuticals
KALV
$713M
| $2.61M | 0.71% |
265,663
+75,000
| +39% | +$738K |
|
38
89bio
ETNB
$1.37B
| $2.47M | 0.67% |
766,774
+442,721
| +137% | +$1.43M |
|
|
DICE
39
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $2.44M | 0.66% |
156,904
+62,904
| +67% | +$976K |
|
40
Galapagos
GLPG
$2.06B
| $2.38M | 0.65% |
42,675
| – | – |
|
|
BCYC
41
Bicycle Therapeutics
BCYC
$492M
| $2.2M | 0.6% |
131,200
+78,000
| +147% | +$1.31M |
|
|
ITOS
42
DELISTED
iTeos Therapeutics
ITOS
| $2.17M | 0.59% |
105,298
+16,000
| +18% | +$330K |
|
|
AERI
43
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $2.17M | 0.59% |
289,040
| – | – |
|
44
Kura Oncology
KURA
$732M
| $2.16M | 0.59% |
117,829
+4,500
| +4% | +$82.5K |
|
|
AFMD
45
DELISTED
Affimed
AFMD
| $1.9M | 0.52% |
686,282
+115,000
| +20% | +$319K |
|
46
Mersana Therapeutics
MRSN
$34.8M
| $1.88M | 0.51% |
406,763
+54,000
| +15% | +$249K |
|
47
Oric Pharmaceuticals
ORIC
$1.03B
| $1.86M | 0.51% |
+415,926
| New | +$1.86M |
|
48
Accuray
ARAY
$165M
| $1.85M | 0.5% |
941,800
| – | – |
|
|
SURF
49
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $1.8M | 0.49% |
1,100,000
+420,000
| +62% | +$689K |
|
|
50
Biomea Fusion
BMEA
$114M
| $1.64M | 0.45% |
136,935
-246,988
| -64% | -$2.96M |
|